It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The effects of heterogeneous infection, vaccination and boosting histories prior to and during pregnancy have not been extensively studied and are likely important for protection of neonates. We measure levels of spike binding antibodies in 4600 patients and their neonates with different vaccination statuses, with and without history of SARS-CoV-2 infection. We investigate neutralizing antibody activity against different SARS-CoV-2 variant pseudotypes in a subset of 259 patients and determined correlation between IgG levels and variant neutralizing activity. We further study the ability of maternal antibody and neutralizing measurements to predict neutralizing antibody activity in the umbilical cord blood of neonates. In this work, we show SARS-CoV-2 vaccination and boosting, especially in the setting of previous infection, leads to significant increases in antibody levels and neutralizing activity even against the recent omicron BA.1 and BA.5 variants in both pregnant patients and their neonates.
Here the authors show that SARS-CoV-2 vaccination and boosting, especially in the setting of previous infection, leads to significant increases in antibody levels and neutralizing activity against omicron BA.1 and BA.5 variants in both pregnant patients and their neonates.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Weill Cornell Medicine, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X)
2 The Rockefeller University, Laboratory of Retrovirology, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519)
3 New York Presbyterian/Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112)
4 Weill Cornell Medicine, Department of Obstetrics & Gynecology, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X)
5 Weill Cornell Medicine, Department of Microbiology and Immunology, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X)
6 Weill Cornell Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X)
7 The Rockefeller University, Laboratory of Retrovirology, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519); The Rockefeller University, Howard Hughes Medical Institute, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519)
8 Weill Cornell Medicine, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X); New York Presbyterian/Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112)